Pangaea Oncology Past Earnings Performance
Past criteria checks 0/6
Pangaea Oncology's earnings have been declining at an average annual rate of -3.9%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 8.3% per year.
Key information
-3.9%
Earnings growth rate
14.8%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 8.3% |
| Return on equity | -25.5% |
| Net Margin | -46.8% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses Breakdown
How Pangaea Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 10 | -5 | 9 | 0 |
| 30 Sep 23 | 8 | -4 | 8 | 0 |
| 30 Jun 23 | 7 | -3 | 6 | 0 |
| 31 Mar 23 | 7 | -3 | 6 | 0 |
| 31 Dec 22 | 7 | -3 | 5 | 0 |
| 30 Sep 22 | 7 | -2 | 5 | 0 |
| 30 Jun 22 | 7 | -2 | 5 | 0 |
| 31 Mar 22 | 7 | -1 | 5 | 0 |
| 31 Dec 21 | 7 | -1 | 4 | 0 |
| 30 Sep 21 | 7 | -1 | 4 | 0 |
| 30 Jun 21 | 7 | -1 | 4 | 0 |
| 31 Mar 21 | 6 | -1 | 4 | 0 |
| 31 Dec 20 | 6 | -2 | 4 | 0 |
| 30 Sep 20 | 6 | -3 | 4 | 0 |
| 30 Jun 20 | 6 | -4 | 4 | 0 |
| 31 Mar 20 | 6 | -4 | 4 | 0 |
| 31 Dec 19 | 6 | -5 | 4 | 0 |
| 30 Sep 19 | 6 | -3 | 4 | 0 |
| 30 Jun 19 | 5 | -2 | 4 | 0 |
| 31 Mar 19 | 6 | -1 | 4 | 0 |
| 31 Dec 18 | 6 | -1 | 4 | 0 |
| 30 Sep 18 | 6 | -2 | 4 | 0 |
| 30 Jun 18 | 6 | -2 | 4 | 0 |
| 31 Mar 18 | 6 | -2 | 4 | 0 |
| 31 Dec 17 | 6 | -2 | 4 | 0 |
| 30 Sep 17 | 6 | -1 | 4 | 0 |
| 30 Jun 17 | 5 | -1 | 4 | 0 |
| 31 Mar 17 | 5 | -1 | 4 | 0 |
| 31 Dec 16 | 5 | -1 | 4 | 0 |
| 30 Sep 16 | 5 | -1 | 4 | 0 |
| 30 Jun 16 | 5 | 0 | 3 | 0 |
| 31 Mar 16 | 4 | 0 | 3 | 0 |
| 31 Dec 15 | 4 | 0 | 3 | 0 |
| 31 Dec 14 | 2 | 0 | 3 | 0 |
| 31 Dec 13 | 3 | 0 | 3 | 0 |
Quality Earnings: PANG is currently unprofitable.
Growing Profit Margin: PANG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PANG is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.
Accelerating Growth: Unable to compare PANG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PANG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Return on Equity
High ROE: PANG has a negative Return on Equity (-25.48%), as it is currently unprofitable.